Advanced Tissue Sciences Inc., of La Jolla, Calif., said it received U.S. Patent No. 6,121,042 titled "Apparatus and Method for Simulating In Vivo Conditions while Seeding and Culturing Three-Dimensional Tissue Constructs." It covers seeding cells onto a biocompatible scaffold and using a closed system bioreactor apparatus to simulate physiologic conditions of nutrient flow, stress and strain.
Alteon Inc., of Ramsey, N.J., said it received U.S. Patent No. 6,121,300 titled "Reversing Advanced Glycosylation Crosslinks Using Heterocyclic Substituted Thiazolium Salts." It covers a new class of A.G.E. crosslink breaker compounds.
Calyx Therapeutics Inc., of Hayward, Calif., said it received U.S. Patent No. 6,127,338 covering a series of small peptides potentially useful for treatment of diabetes. The patent covers sequences and pharmaceutical compositions of three orally active peptides that lower blood glucose levels in animal models of diabetes.
Commonwealth Biotechnologies Inc., of Richmond, Va., said it was issued a patent for its automated DNA sequencing reagent, AccuTrac. It protects the reagent and the process for which the reagent is used.
Demegen Inc., of Pittsburgh, said it received U.S. Patent No. 6,084,156 titled "Plants Producing Lytic Peptides." It covers transgenic plants capable of expressing unique Demegen peptides.
Eukarion Inc., of Bedford, Mass., said it received a patent covering several of its synthetic catalytic scavenger compounds. It covers compounds for the topical treatment of a wide range of skin disorders.
Galenica Pharmaceuticals Inc., of Frederick, Md., said it received U.S. Patent No. 5,977,725 titled "Triterpene Saponin Analogs Having Adjuvant and Immunostimulatory Activity," and U.S. Patent No. 6,080,725 titled "Immunostimulating and Vaccine Compositions Employing Saponin Analog Adjuvants and Uses Thereof." They cover the composition of Galenica's immunostimulatory agent GPI-0100 and its use in vaccine formulations.
Mycogen Plant Sciences Inc., of Indianapolis, said it received U.S. Patent No. 6,114,138. It covers foundational work enabling use of Bt delta-endotoxin genes to impart insect resistance in crops.
Myriad Genetics Inc., of Salt Lake City, said it received U.S. Patent No. 6,090,578. It covers the composition of matter of the full-length protein produced by the p16 tumor suppressor gene and antibodies against the p16 protein.
Packard BioScience Co., of Meriden, Conn. said it received U.S. Patent No. 6,112,605, titled "Method for Dispensing and Determining a Microvolume of Sample Liquid." It covers methods and devices to enable low-cost, industrial-scale manufacture of protein and DNA microarrays using robot-controlled, inkjet-style printing technology.
Procyon BioPharma Inc., of Montreal, said it received U.S. Patent No. 6,107,103 titled "Assay for PSP94 Protein." It covers claims for more accurately assessing the stage of prostate cancer in patients and a general prostate cancer screening method.